Osteosarcoma Institute (OSI): LOI

Clinical trials: to improve EFS at 4 months, beyond the range of 12%. Requires detailed timetables for protocol development and all regulatory stages. Funding: up to $800,000 / 3 years.

Correlative studies: to generate data for future clinical studies to improve survival of recurrent and metastatic osteosarcoma patients. Funding: $250,000 – $500,000 / 2 years.

Translational studies: For a preclinical dataset for metastasis. Funding: up to $500,000 / 2 years.

https://osinst.org/rfps/call-for-letters-of-intent-for-studies-that-will-improve-outcomes-for-recurrent-osteosarcoma-patients/